Inside-Filings
Projekt anfragen

Biocryst Pharmaceuticals Inc (BCRX)

BIOCRYST PHARMACEUTICALS INC
Healthcare · Biotechnology
TickerBCRXBörseNasdaq
ISINUS09058V1035CIK0000882796
8,70
Schluss · 12.06.2026
1T+2,4 %1W+3,4 %1M−9,4 %3M+5,8 %6M+14,9 %1J−16,3 %
GCS 61 → +0,0
TSI -9,9 · -10,5 ▲ 12.06.
8-K 5.02 12.06.26· 2T
Insider ▼ 18.05.26· 27T
PDF

Glück Conviction Score™ ⓘ

BCRX BIOCRYST PHARMACEUTICALS INC
Conviction Score
61
Stark
Timing / Risiko Ruhig· 57
Effektiv: Stark Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
81,8
69 neu, 116 erhöht, 555,6M $ netto
Aktivist
24,6
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)

Score-Verlauf (90 Tage)

Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.

Kursverlauf (12 Monate)

Technische Indikatoren

55
Technical-Score: 55 / 100 (informativ, keine Anlageempfehlung)
Bullisch-Anteil 25 % — 3 bullisch / 3 bärisch / 6 neutral

Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).

IndikatorSignalGewichtWertDetailBeitrag
Kurs vs SMA50Bärisch10 %8.95-2.8 % vs SMA50
Kurs vs SMA200Bullisch15 %7.92+9.8 % vs SMA200
SMA-CrossBullisch10 %GOLDENvor 50 Tagen @ 9.38
EMA20 vs EMA50Bärisch5 %8.60EMA50: 8.72
MACD-HistogrammBullisch10 %0.009Bullisch
RSI(14)Neutral10 %50.7Neutral (30–70)
Stoch %K(14)Neutral5 %54.7Neutral
ADX(14)+DINeutral10 %18.6+DI: 22.8 / −DI: 26.4
Z-Score(60)Neutral5 %-0.75In Range
52W-PositionNeutral5 %59.1 %Hoch 10.40 / Tief 6.24
Bollinger(20,2σ)Neutral5 %58.8 %Upper 9.18 / Mid 8.60 / Lower 8.02
LinReg-Slope(60)Bärisch10 %-0.0221R²=0.66 / annualisiert -61.5 %

Insider-Transaktionen (12 Monate) ⓘ

DatumInsiderRolleTypStückzahlKursWert (USD)ΔTrend
2026-05-18McKee Amy EDirectorOpen Market Sale-11.1808,97-100.284,60-23,3%
2026-05-13Barnes Alane POfficer, Chief Legal OfficerOpen Market Sale-62.5009,54-596.250,00-138,6%
2026-03-20HEGGIE THERESADirectorOpen Market Sale-49.93310,11-504.822,63-117,3%
2026-03-16Barnes Alane POfficer, Chief Legal OfficerOpen Market Sale-150.0009,15-1.372.500,00-319,0%
2025-12-22Barnes Alane POfficer, Chief Legal OfficerOpen Market Sale-21.7737,65-166.563,45-38,7%
2025-12-15Barnes Alane POfficer, Chief Legal OfficerOpen Market Sale-21.2107,65-162.256,50-37,7%
2025-12-03Barnes Alane POfficer, Chief Legal OfficerOpen Market Sale-19.7707,65-151.240,50-35,2%
2025-12-02Barnes Alane POfficer, Chief Legal OfficerOpen Market Sale-50.9067,21-367.215,52-85,4%
2025-12-01Barnes Alane POfficer, Chief Legal OfficerOpen Market Sale-91.0047,10-646.510,62-150,3%
2025-11-13SANDERS MACHELLEDirectorOpen Market Sale-9.6007,14-68.544,00-15,9%
2025-08-13HEGGIE THERESADirectorOpen Market Sale-70.0008,51-595.868,00-138,5%

Fondsaktivität (Vorquartalsvergleich) ⓘ

FondsAktuell (Stk)Vorquartal (Stk)Veränderung (Stk)Wert (USD)StatusΔTrend
BlackRock, Inc.22.650.98821.137.7911.513.197215.637.401Aufgestockt+7,2%
VANGUARD GROUP INC22.273.375022.273.375173.732.325Neu+100,0%
RA CAPITAL MANAGEMENT, L.P.15.827.18615.827.1860150.674.811Unverändert0,0%
DEERFIELD MANAGEMENT COMPANY, L.P.15.038.00014.341.000697.000143.161.760Aufgestockt+4,9%
STATE STREET CORP12.208.36011.073.2111.135.149116.223.587Aufgestockt+10,3%
VANGUARD CAPITAL MANAGEMENT LLC11.135.762011.135.762106.012.454Neu+100,0%
TCG Crossover Management, LLC11.020.968011.020.968104.919.615Neu+100,0%
JANUS HENDERSON GROUP PLC8.908.5067.404.3861.504.12084.853.520Aufgestockt+20,3%
PERCEPTIVE ADVISORS LLC7.434.0333.162.5294.271.50470.771.994Aufgestockt+135,1%
Vestal Point Capital, LP7.025.0002.250.0004.775.00066.878.000Aufgestockt+212,2%
TWO SIGMA INVESTMENTS, LP6.392.6284.515.3171.877.31160.857.819Aufgestockt+41,6%
GEODE CAPITAL MANAGEMENT, LLC5.782.7765.053.786728.99055.063.276Aufgestockt+14,4%
Kynam Capital Management, LP5.680.7959.366.526-3.685.73154.081.168Reduziert-39,4%
BANK OF AMERICA CORP /DE/5.091.7651.535.5573.556.20848.473.603Aufgestockt+231,6%
Aberdeen Group plc5.040.670913.5934.127.07747.987.178Aufgestockt+451,7%
UBS Group AG4.943.9945.271.914-327.92047.066.823Reduziert-6,2%
Frazier Life Sciences Management, L.P.4.009.24004.009.24038.167.965Neu+100,0%
Royalty Pharma Sub-Manager, LLC3.846.1543.846.154036.615.386Unverändert0,0%
Nuveen, LLC3.819.2633.612.366206.89736.359.384Aufgestockt+5,7%
TWO SIGMA ADVISERS, LP4.089.11204.089.11231.895.074Neu+100,0%
SUSQUEHANNA INTERNATIONAL GROUP, LLP3.151.7041.328.3931.823.31130.004.222Aufgestockt+137,3%
Eversept Partners, LP3.039.8202.992.89546.92528.939.086Aufgestockt+1,6%
RFG Advisory, LLC2.870.70002.870.70027.329.064Neu+100,0%
Fisher Asset Management, LLC2.733.2532.467.567265.68626.020.567Aufgestockt+10,8%
DIMENSIONAL FUND ADVISORS LP2.690.6511.228.8521.461.79925.614.944Aufgestockt+119,0%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC2.350.4052.004.939345.46622.375.856Aufgestockt+17,2%
GOLDMAN SACHS GROUP INC2.347.4433.212.785-865.34222.347.654Reduziert-26,9%
BAKER BROS. ADVISORS LP2.822.72702.822.72722.017.271Neu+100,0%
Candriam S.C.A.2.286.84102.286.84121.770.726Neu+100,0%
RICE HALL JAMES & ASSOCIATES, LLC2.230.1051.904.146325.95921.230.600Aufgestockt+17,1%
NORTHERN TRUST CORP2.104.7251.856.903247.82220.036.982Aufgestockt+13,3%
MORGAN STANLEY2.022.9881.745.563277.42519.258.852Aufgestockt+15,9%
Nantahala Capital Management, LLC1.987.3971.356.377631.02018.920.019Aufgestockt+46,5%
STIFEL FINANCIAL CORP1.825.1841.824.51766717.375.751Aufgestockt0,0%
Qube Research & Technologies Ltd2.164.16202.164.16216.880.464Neu+100,0%
Parkman Healthcare Partners LLC1.708.099900.057808.04216.261.102Aufgestockt+89,8%
ORBIMED ADVISORS LLC1.425.2001.741.800-316.60013.567.904Reduziert-18,2%
Legal & General Group Plc1.411.199210.9991.200.20013.434.615Aufgestockt+568,8%
Schonfeld Strategic Advisors LLC1.337.693141.4491.196.24412.734.836Aufgestockt+845,7%
Invesco Ltd.1.308.8131.354.897-46.08412.459.899Reduziert-3,4%
BNP PARIBAS FINANCIAL MARKETS1.302.2572.542.714-1.240.45712.397.487Reduziert-48,8%
Man Group plc1.293.300407.850885.45012.312.216Aufgestockt+217,1%
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND1.227.04001.227.04011.681.421Neu+100,0%
JANE STREET GROUP, LLC1.223.2381.547.457-324.21911.645.225Reduziert-21,0%
CITADEL ADVISORS LLC1.214.9461.512.202-297.25611.566.285Reduziert-19,7%
JUPITER ASSET MANAGEMENT LTD1.196.3711.197.619-1.24811.389.452Reduziert-0,1%
JACOBS LEVY EQUITY MANAGEMENT, INC1.004.3731.031.488-27.1159.561.631Reduziert-2,6%
Elmind Capital, LP1.000.0002.150.000-1.150.0009.520.000Reduziert-53,5%
Point72 Asset Management, L.P.1.213.57601.213.5769.465.893Neu+100,0%
Rosalind Advisors, Inc.923.0570923.0578.787.503Neu+100,0%

Top-Fondshalter (Stand: 31.03.2026) ⓘ

FondsAnteileVorquartal (Stk)ΔWert (USD)Anteil (%)
BlackRock, Inc.22.650.98821.137.791+7,2%215.637.4019,84
RA CAPITAL MANAGEMENT, L.P.15.827.18615.827.1860,0%150.674.8116,88
DEERFIELD MANAGEMENT COMPANY, L.P.15.038.00014.341.000+4,9%143.161.7606,53
STATE STREET CORP12.208.36011.073.211+10,3%116.223.5875,30
VANGUARD CAPITAL MANAGEMENT LLC11.135.7620+100,0%106.012.4544,84
TCG Crossover Management, LLC11.020.9680+100,0%104.919.6154,79
JANUS HENDERSON GROUP PLC8.908.5067.404.386+20,3%84.853.5203,87
PERCEPTIVE ADVISORS LLC7.434.0333.162.529+135,1%70.771.9943,23
Vestal Point Capital, LP7.025.0002.250.000+212,2%66.878.0003,05
TWO SIGMA INVESTMENTS, LP6.392.6284.515.317+41,6%60.857.8192,78
GEODE CAPITAL MANAGEMENT, LLC5.782.7765.053.786+14,4%55.063.2762,51
Kynam Capital Management, LP5.680.7959.366.526-39,4%54.081.1682,47
BANK OF AMERICA CORP /DE/5.091.7651.535.557+231,6%48.473.6032,21
Aberdeen Group plc5.040.670913.593+451,7%47.987.1782,19
UBS Group AG4.943.9945.271.914-6,2%47.066.8232,15
Frazier Life Sciences Management, L.P.4.009.2400+100,0%38.167.9651,74
Royalty Pharma Sub-Manager, LLC3.846.1543.846.1540,0%36.615.3861,67
Nuveen, LLC3.819.2633.612.366+5,7%36.359.3841,66
SUSQUEHANNA INTERNATIONAL GROUP, LLP3.151.7041.328.393+137,3%30.004.2221,37
Eversept Partners, LP3.039.8202.992.895+1,6%28.939.0861,32

Halter-Trend (6 Quartale)

PeriodeStatusHalterAnteile (Mio)Wert (Mio $)
31.03.2026✓300277,92.609
31.12.2025✓275219,51.676
30.09.2025✓284204,71.518
30.06.2025✓292201,61.736
31.03.2025✓267180,81.314
31.12.2024✓252170,71.242

Top 10 Neueinsteiger

FondsAnteileWert (USD) ⓘ
RA CAPITAL MANAGEMENT, L.P.15.827.186123.452.051
Royalty Pharma Sub-Manager, LLC3.846.15430.000.001
PERCEPTIVE ADVISORS LLC3.162.52924.667.726
BAKER BROS. ADVISORS LP2.822.72722.017.271
Vestal Point Capital, LP2.250.00017.550.000
Elmind Capital, LP2.150.00016.770.000
Nantahala Capital Management, LLC1.356.37710.579.741
DIMENSIONAL FUND ADVISORS LP1.228.8529.585.046
Hudson Bay Capital Management LP1.017.3747.935.517
Aberdeen Group plc913.5937.126.025

Top 10 Aufstocker

FondsAnteileΔ Anteile ⓘΔ % ⓘWert (USD) ⓘ
JANUS HENDERSON GROUP PLC7.404.3867.310.745+7807.2 %57.791.233
DEERFIELD MANAGEMENT COMPANY, L.P.14.341.0002.172.000+17.8 %111.859.800
Eversept Partners, LP2.992.8951.619.270+117.9 %23.344.581
STATE STREET CORP11.073.2111.265.773+12.9 %86.371.046
SUSQUEHANNA INTERNATIONAL GROUP, LLP1.328.393984.732+286.5 %10.361.465
Point72 Asset Management, L.P.1.213.576975.389+409.5 %9.465.893
GW&K Investment Management, LLC3.160.924963.159+43.8 %24.655
ORBIMED ADVISORS LLC1.741.800840.300+93.2 %13.586.040
JACOBS LEVY EQUITY MANAGEMENT, INC1.031.488661.025+178.4 %8.045.606
HRT FINANCIAL LP716.826658.920+1137.9 %5.591

Top 10 Verkäufer

FondsAnteileΔ Anteile ⓘΔ % ⓘWert (USD) ⓘ
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP66.244-5.159.742-98.7 %516.703
MORGAN STANLEY1.745.563-3.457.396-66.5 %13.615.396
Assenagon Asset Management S.A.359.580-2.733.012-88.4 %2.804.724
JANE STREET GROUP, LLC1.547.457-1.149.289-42.6 %12.070.164
JUPITER ASSET MANAGEMENT LTD1.197.619-858.296-41.7 %9.341.428
ACADIAN ASSET MANAGEMENT LLC85.300-754.103-89.8 %662
UBS Group AG5.271.914-703.823-11.8 %41.120.929
DEUTSCHE BANK AG\491.086-577.929-54.1 %3.830.471
VOLORIDGE INVESTMENT MANAGEMENT, LLC449.743-507.278-53.0 %3.507.995
Connor, Clark & Lunn Investment Management Ltd.357.086-491.476-57.9 %2.785.271

Aktivisten & Großaktionäre (13D/13G) ⓘ

DatumInvestorTypAnteilAktienΔZweck
12.05.2026STATE STREET CORPORATIONPassiv (13G)4,90 %12.208.360-0,40 pp
29.04.2026Vanguard Capital ManagementPassiv (13G)5,16 %12.961.172Neu
26.03.2026The Vanguard GroupPassiv (13G/A)Ausstieg0-10,02 pp
12.02.2026James E. FlynnPassiv (13G/A)6,81 %14.341.000+1,01 pp
12.02.2026Deerfield Management Company, L.P.Passiv (13G/A)6,81 %14.341.000+1,01 pp
12.02.2026Deerfield Mgmt, L.P.Passiv (13G/A)6,81 %14.341.000+1,01 pp
12.02.2026Deerfield Partners, L.P.Passiv (13G/A)6,81 %14.341.000+1,01 pp
09.02.2026STATE STREET CORPORATIONPassiv (13G)5,30 %11.073.211+1,00 pp
12.11.2025Rajeev ShahPassiv (13G)7,30 %15.302.186+7,30 pp
12.11.2025RA Capital Management, L.P.Passiv (13G)7,30 %15.302.186+7,30 pp
12.11.2025Peter KolchinskyPassiv (13G)7,30 %15.302.186+7,30 pp
12.11.2025RA Capital Healthcare Fund, L.P.Passiv (13G)7,30 %15.302.186Neu
19.09.2025James E. FlynnPassiv (13G)5,80 %12.169.000+1,66 pp
19.09.2025Deerfield Management Company, L.P.Passiv (13G)5,80 %12.169.000Neu
19.09.2025Deerfield Mgmt, L.P.Passiv (13G)5,80 %12.169.000+1,66 pp
19.09.2025Deerfield Partners, L.P.Passiv (13G)5,80 %12.169.000+1,66 pp
15.05.2025Behzad AghazadehPassiv (13G/A)4,20 %8.700.000-2,20 pp
15.05.2025Avoro Capital Advisors LLCPassiv (13G/A)4,20 %8.700.000-2,20 pp
17.04.2025BlackRock, Inc.Passiv (13G/A)8,40 %17.483.490Neu
07.11.2024The Vanguard GroupPassiv (13G/A)10,02 %20.730.939+0,21 pp
07.11.2024The Vanguard GroupPassiv (13G/A)9,81 %20.306.5960,00 pp
04.11.2024The Vanguard GroupPassiv (13G/A)9,81 %20.306.596+1,14 pp
17.10.2024STATE STREET CORPORATIONPassiv (13G/A)4,30 %8.849.588Neu
10.09.2024. BlackRock, Inc.Passiv (13G/A)10,20 %21.042.472+1,10 pp
14.02.2024Julian C. BakerPassiv (13G/A)4,98 %10.204.089-4,97 pp
14.02.2024Baker Bros. Advisors (GP) LLCPassiv (13G/A)4,94 %10.126.176-4,97 pp
14.02.2024Baker Bros. Advisors LPPassiv (13G/A)4,94 %10.126.176-4,97 pp
14.02.2024Felix J. BakerPassiv (13G/A)4,98 %10.204.089-4,97 pp
14.02.2024Behzad AghazadehPassiv (13G)6,40 %13.050.000Neu
14.02.2024Avoro Capital Advisors LLCPassiv (13G)6,40 %13.050.000Neu
13.02.2024The Vanguard GroupPassiv (13G/A)8,67 %17.763.720+1,05 pp
24.01.2024. BlackRock, Inc.Passiv (13G/A)9,10 %18.681.370+1,10 pp
24.01.2024: STATE STREET CORPORATIONPassiv (13G/A)6,24 %0+0,27 pp
14.02.2023Baker Bros. Advisors (GP) LLCPassiv (13G/A)9,91 %19.106.8810,00 pp
14.02.2023Felix J. BakerPassiv (13G/A)9,95 %19.184.7940,00 pp
14.02.2023Baker Bros. Advisors LPPassiv (13G/A)9,91 %19.106.8810,00 pp
14.02.2023Julian C. BakerPassiv (13G/A)9,95 %19.184.7940,00 pp
09.02.2023The Vanguard GroupPassiv (13G/A)7,62 %14.204.395+2,39 pp
06.02.2023: STATE STREET CORPORATIONPassiv (13G/A)5,97 %0+1,39 pp
03.02.2023. BlackRock, Inc.Passiv (13G/A)8,00 %14.918.955-0,20 pp

US Congress Trades (STOCK Act)

DatumMitgliedParteiKammerTypBetrag-Bereich
13.11.2025Gilbert Cisneros–HouseKauf$1,001 – $15,000

Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →

Stammdaten

BioCryst Pharmaceuticals, Inc., ein Biotechnologieunternehmen, entdeckt neuartige, orale und kleine Molekülmedikamente. Das Unternehmen vermarktet Peramivir-Injektion, einen intravenösen Neuraminidase-Inhibitor zur Behandlung der unkomplizierten Grippe unter den Namen RAPIVAB, RAPIACTA und PERAMIFLU; und ORLADEYO, einen oralen Serineprotease-Inhibitor zur Behandlung von hereditärem Angioödem. Das Unternehmen entwickelt auch BCX9930, einen oralen Faktor-D-Inhibitor, der sich in Phase-II-klinischen Studien für komplementvermittelte Krankheiten befindet; BCX9250, einen oralen Activin-Rezeptor-ähnlichen Kinase-2-Inhibitor, der sich in Phase-I-klinischen Studien zur Behandlung der Fibrodysplasia ossificans progressiva befindet; und Galidesivir, einen RNA-abhängigen-RNA-Polymerase-Inhibitor, der sich in Phase-I-klinischen Studien zur Behandlung verschiedener RNA-Viren, einschließlich Marburg, Gelbfieber, Ebola und Zika, befindet. Das Unternehmen hat Kooperationen und Lizenzbeziehungen mit Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; dem U.S. Department of Health and Human Services; und The University of Alabama at Birmingham sowie Albert Einstein College of Medicine of Yeshiva University und Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. wurde 1986 gegründet und hat seinen Sitz in Durham, North Carolina.

Unternehmen & Branche

NameBIOCRYST PHARMACEUTICALS INC
TickerBCRX
CIK0000882796
BoerseNasdaq
SektorHealthcare
IndustrieBiotechnology
SIC2836 · Biological Products, (No Diagnostic Substances)

Wertpapier & Kennzahlen

CUSIP09058v103
ISINUS09058V1035
TypCommon Stock
Marktkapitalisierung1,74 Mrd. USD
KGV (P/E)6,77
Beta0,60

Bewertung

EV/EBITDA4,9
FCF-Rendite19,9 % vs. -5,6 % (2021) ▲

Qualität & Bilanz

Nettoverschuldung/EBITDA-0,2
Zinsdeckungsgrad4,3 vs. -3,0 (2021) ▲

Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →

Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
Kennzahl20212022202320242025Verlauf
Bewertung
FCF-Rendite-5,6 %-7,5 %-7,7 %-3,3 %20,9 %
Qualität & Bilanz
Zinsdeckungsgrad-3,0-1,5-1,00,04,3

Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).

Externe Quelle: SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »

Finanzkennzahlen (SEC XBRL) ⓘ

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2026-03-3110-Q-721.812.000-2,98465.052.000-553.843.000
2025-12-3110-K263.861.0001,21514.158.000-119.153.000
2025-09-3010-Q12.899.0000,06446.424.000-387.889.000
2025-06-3010-Q5.085.0000,02457.188.000-421.594.000
2025-03-3110-Q32.0000,00480.047.000-451.927.000
2024-12-3110-K-88.881.000-0,43490.420.000-475.934.000
2024-09-3010-Q-14.033.000-0,07491.254.000-468.563.000
2024-06-3010-Q-12.674.000-0,06472.419.000-475.606.000
2024-03-3110-Q-35.379.000-0,17467.892.000-476.167.000
2023-12-3110-K-226.539.000-1,18516.960.000-455.528.000
2023-09-3010-Q-36.149.000-0,19522.924.000-410.986.000
2023-06-3010-Q-75.326.000-0,40529.885.000-388.713.000
2023-03-3110-Q-53.333.000-0,28509.737.000-328.287.000
2022-12-3110-K-247.116.000-1,33550.000.000-294.597.000
2022-09-3010-Q-42.520.000-0,23558.594.000-242.659.000
2022-06-3010-Q-58.859.000-0,32510.538.000-213.232.000
2022-03-3110-Q-74.196.000-0,40527.720.000-164.215.000
2021-12-3110-K-184.062.000-1,03588.151.000-106.986.000
2021-09-3010-Q-58.801.000-0,33265.763.000-147.044.000
2021-06-3010-Q-43.198.000-0,24277.284.000-106.075.000

Umsatz nach Segmenten & Regionen ⓘ

Geschäftssegmente

SegmentFY 2025FY 2024FY 2023FY 2022FY 2021AnteilΔTrend
Product623,2 Mio.442,7 Mio.324,7 Mio.267,7 Mio.136,4 Mio.35,5 %+40,8%
ORLADEYO601,8 Mio.437,7 Mio.326,0 Mio.––34,2 %+37,5%
License And Other Revenues251,7 Mio.––––14,3 %Neu
License244,0 Mio.––––13,9 %Neu
Other Income From Contract With Customer29,0 Mio.13,1 Mio.5,4 Mio.––1,7 %+122,3%
Collaborative And Other Research And Development7,7 Mio.8,0 Mio.6,7 Mio.214.0005,9 Mio.0,4 %-4,2%
Royalty–––2,9 Mio.-100.000––
Milestone––––15,0 Mio.––

Quartalsergebnisse (Earnings) ⓘ

QuartalStichtagVerkündetUmsatzEPS
Q1 202631.03.202606.05.2026–-2,98
Q3 202530.09.202504.11.2025–0,06
Q2 202530.06.202504.11.2025–0,02
Q1 202531.03.202506.05.2026–0,00
Q3 202430.09.202404.11.2025–-0,07
Q2 202430.06.202404.11.2025–-0,06
Q1 202431.03.202404.11.2025–-0,17
Q3 202330.09.202305.11.2024–-0,19
Q2 202330.06.202305.11.2024–-0,40

Einreichungs-Historie (10-K / 10-Q)

SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte (10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die Tage zwischen Berichtsstichtag und tatsächlicher Einreichung. Suffix /A kennzeichnet nachträgliche Berichtigungen.

Eingereicht Form Berichtsperiode Verzögerung
06.05.2026 10-Q 31.03.2026 36 Tage SEC »
26.02.2026 10-K 31.12.2025 57 Tage SEC »
04.11.2025 10-Q 30.09.2025 35 Tage SEC »
05.08.2025 10-Q 30.06.2025 36 Tage SEC »
06.05.2025 10-Q 31.03.2025 36 Tage SEC »
25.02.2025 10-K 31.12.2024 56 Tage SEC »
05.11.2024 10-Q 30.09.2024 36 Tage SEC »
06.08.2024 10-Q 30.06.2024 37 Tage SEC »
07.05.2024 10-Q 31.03.2024 37 Tage SEC »
27.02.2024 10-K 31.12.2023 58 Tage SEC »
08.11.2023 10-Q 30.09.2023 39 Tage SEC »
07.08.2023 10-Q 30.06.2023 38 Tage SEC »
08.05.2023 10-Q 31.03.2023 38 Tage SEC »
27.02.2023 10-K 31.12.2022 58 Tage SEC »
04.11.2022 10-Q 30.09.2022 35 Tage SEC »
05.08.2022 10-Q 30.06.2022 36 Tage SEC »
09.05.2022 10-Q 31.03.2022 39 Tage SEC »
28.02.2022 10-K 31.12.2021 59 Tage SEC »
04.11.2021 10-Q 30.09.2021 35 Tage SEC »
09.08.2021 10-Q 30.06.2021 40 Tage SEC »
07.05.2021 10-Q 31.03.2021 37 Tage SEC »
01.03.2021 10-K 31.12.2020 60 Tage SEC »
06.11.2020 10-Q 30.09.2020 37 Tage SEC »
07.08.2020 10-Q 30.06.2020 38 Tage SEC »

Kritische 8-K Meldungen ⓘ

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (12.06.2026)
DatumMeldungSchwereFilingAuszug
12.06.2026Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
23.01.2026Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
11.12.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
14.10.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
11.08.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
31.07.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
07.07.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
16.06.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
04.06.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
01.05.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
10.04.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
04.03.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
13.06.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
01.12.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
11.07.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
14.06.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
14.09.2022Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
07.06.2022Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
08.02.2022Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…
20.09.2021Item 5.02 — Abgang SchlüsselpersonenHOCHSECItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers…

Hinweis

Erweitert ×